NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free SNTI Stock Alerts $0.38 +0.02 (+5.56%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.32▼$0.3850-Day Range$0.28▼$0.4752-Week Range$0.27▼$1.10Volume175,607 shsAverage Volume177,692 shsMarket Capitalization$17.39 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Senti Biosciences alerts: Email Address Senti Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,478.9% Upside$6.00 Price TargetShort InterestHealthy0.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector370th out of 928 stocksBiological Products, Except Diagnostic Industry48th out of 143 stocks 3.5 Analyst's Opinion Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSenti Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.60% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently decreased by 22.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNTI. Previous Next 3.6 News and Social Media Coverage News SentimentSenti Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for SNTI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Senti Biosciences Stock (NASDAQ:SNTI)Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More SNTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNTI Stock News HeadlinesApril 30, 2024 | globenewswire.comSenti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)April 23, 2024 | americanbankingnews.comSenti Biosciences (NASDAQ:SNTI) Shares Down 8.7% May 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 23, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsMarch 21, 2024 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsFebruary 4, 2024 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), Guidance and ForecastJanuary 8, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramJanuary 5, 2024 | marketwatch.comSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer TreatmentMay 2, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 5, 2024 | finance.yahoo.comSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramDecember 22, 2023 | finance.yahoo.comWhy Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?December 22, 2023 | markets.businessinsider.comSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic MalignanciesDecember 22, 2023 | finance.yahoo.comSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNovember 24, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 13, 2023 | finance.yahoo.comSenti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 11, 2023 | morningstar.comSenti Biosciences Inc SNTINovember 7, 2023 | msn.comWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?November 7, 2023 | msn.comWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?November 7, 2023 | msn.comWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?November 6, 2023 | finance.yahoo.comSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaOctober 31, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingOctober 9, 2023 | bizjournals.comGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facilitySeptember 27, 2023 | investing.comShanti Overseas India Ltd (SNTI)September 27, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingSeptember 26, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming ConferencesAugust 15, 2023 | msn.comChardan Capital Reiterates Senti Biosciences (SNTI) Buy RecommendationAugust 11, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesSee More Headlines Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees48Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,478.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,060,000.00 Net Margins-2,692.82% Pretax Margin-3,256.77% Return on Equity-74.59% Return on Assets-48.22% Debt Debt-to-Equity RatioN/A Current Ratio5.62 Quick Ratio5.62 Sales & Book Value Annual Sales$1.98 million Price / Sales8.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.25Miscellaneous Outstanding Shares45,755,000Free Float40,036,000Market Cap$17.39 million OptionableNot Optionable Beta2.96 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Timothy K. Lu M.D. (Age 43)Ph.D., Co-founder, CEO, President & Director Comp: $811.26kDr. James J. Collins Ph.D. (Age 57)Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director Comp: $41.49kDr. Deborah A. Knobelman Ph.D. (Age 50)CFO, Head of Corporate Development & Treasurer Comp: $600.22kMs. Susan D. Berland (Age 69)Senior Financial Executive & Independent Director Comp: $54.23kDr. Kanya Rajangam M.D. (Age 51)Ph.D., Head of Research & Development and Chief Medical Officer Comp: $679.71kDr. Wilson Wong Ph.D.Scientific Co-Founder & Member of Scientific Advisory BoardMr. Mike RheeSenior VP of Legal Affairs & Corporate SecretarySusan KahlertControllerMore ExecutivesKey CompetitorsTevogen BioNASDAQ:TVGNPharmaCyte BiotechNASDAQ:PMCBAptose BiosciencesNASDAQ:APTOAIM ImmunoTechNYSE:AIMCoeptis TherapeuticsNASDAQ:COEPView All CompetitorsInstitutional Ownership8VC GP I LLCBought 2,537,558 shares on 2/12/2024Ownership: 5.697%View All Institutional Transactions SNTI Stock Analysis - Frequently Asked Questions Should I buy or sell Senti Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNTI shares. View SNTI analyst ratings or view top-rated stocks. What is Senti Biosciences' stock price target for 2024? 1 Wall Street research analysts have issued 12-month price targets for Senti Biosciences' shares. Their SNTI share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,478.9% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts. How have SNTI shares performed in 2024? Senti Biosciences' stock was trading at $0.66 at the start of the year. Since then, SNTI stock has decreased by 42.4% and is now trading at $0.38. View the best growth stocks for 2024 here. Are investors shorting Senti Biosciences? Senti Biosciences saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 165,200 shares, a decline of 22.7% from the March 31st total of 213,800 shares. Based on an average daily volume of 81,400 shares, the short-interest ratio is presently 2.0 days. Approximately 0.6% of the shares of the company are short sold. View Senti Biosciences' Short Interest. When is Senti Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SNTI earnings forecast. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) posted its earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative net margin of 2,692.82% and a negative trailing twelve-month return on equity of 74.59%. What ETF holds Senti Biosciences' stock? ARK Genomic Revolution ETF holds 1,615,986 shares of SNTI stock, representing 0.04% of its portfolio. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNTI) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
